NEW YORK (Reuters) - Global equity markets edged higher on Monday as Wall Street rose on Internet and healthcare stocks, while declining yields on government debt also initially provided U.S. equities a lift.
Pfizer’s failed bid for AstraZeneca weighed on European shares earlier in the session, with the British drugmaker the biggest drag on the FTSE 100 .FTSE in London and the pan-regional FTSEurofirst 300 index .FTEU3.
But Pfizer rebounded on the failed bid. At one point, it was the second-largest contributor to gains in the S&P 500 index, after Apple. Pfizer rose 0.5 percent at $29.28 a share, while AstraZeneca closed down 11.1 percent in London.
Treasuries at first rallied. Yields on the benchmark 10-year U.S. Treasury note fell to 2.51 percent, near October lows, but later traded higher at almost 2.55 percent.
Analysts had expected interest rates to rise, but with rates touching seven-month lows, the bond rally has helped U.S. stocks and kept at bay a long-expected correction.
“The big story is the bond market, that is the one thing that stands out like a sore thumb,” said Stephen Massocca, managing director at Wedbush Equity Management LLC in San Francisco.
“If we did not get this big decrease in rates, the (stock) market would’ve corrected,” Massocca said. “It is maybe preventing a decline, of which we are a little overdue in the stock market.”
The Dow Jones industrial average .DJI closed up 20.55 points, or 0.12 percent, to 16,511.86. The S&P 500 .SPX gained 7.22 points, or 0.38 percent, to 1,885.08 and the Nasdaq Composite .IXIC added 35.227 points, or 0.86 percent, to 4,125.815.
“Equities remain a better choice than bonds or cash this year, but on a near-term basis they might succumb to gravity,” said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.
“The listlessness in the market shows the struggle investors are having right now: valuations are full but not stretched, and there’s a lack of decisive evidence that the economy will kick into higher growth and justify these valuations.”
MSCI’s all-world equity index .MIWD00000PUS, which tracks shares in 45 nations, rose 0.11 percent to 415.22. MSCI’s emerging markets index .MSCIEF rose 0.35 percent.
The pan-European FTSEurofirst 300 index .FTEU3, which last week hit a 6-year high of 1,372.81 points, closed down 0.19 percent at 1,358.91 points.
Benchmark 10-year U.S. Treasury notes were last down 8/32 in price to yield 2.5463 percent.
The dollar fell as low as 101.11 yen, the weakest since early February. It was last at 101.45, down 0.04 percent.
The euro gained 0.11 percent on Monday to $1.3707.
U.S. oil prices rose near one-month high as a weak dollar prompted buying, while Brent prices fell as concerns about China’s slowing economy outweighed the impact of low Libyan output.
Brent settled down 38 cents to $109.37 a barrel. U.S. crude rose 59 cents to settle at $102.93.
Additional reporting by Natsuko Waki in London, reporting by Herbert Lash; Editing by Chris Reese, Chizu Nomiyama and Nick Zieminski